Blueprint Medicines (NASDAQ:BPMC) PT Raised to $168.00 at The Goldman Sachs Group

Blueprint Medicines (NASDAQ:BPMC) had its target price lifted by analysts at The Goldman Sachs Group from $121.00 to $168.00 in a research report issued on Monday, Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price objective suggests a potential upside of 58.21% from the company’s current price.

BPMC has been the subject of several other research reports. StockNews.com raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday. Citigroup increased their price objective on Blueprint Medicines from $65.00 to $76.00 and gave the stock a “sell” rating in a research note on Friday. Stifel Nicolaus raised their target price on Blueprint Medicines from $120.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, April 26th. JMP Securities boosted their target price on Blueprint Medicines from $114.00 to $125.00 and gave the stock a “market outperform” rating in a report on Friday. Finally, Barclays raised their target price on Blueprint Medicines from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Blueprint Medicines has an average rating of “Moderate Buy” and a consensus target price of $100.31.

Blueprint Medicines Stock Down 0.9 %

Shares of BPMC stock traded down $1.00 on Monday, hitting $106.19. The stock had a trading volume of 259,091 shares, compared to its average volume of 772,091. The stock has a market cap of $6.50 billion, a price-to-earnings ratio of -22.14 and a beta of 0.65. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.76 and a quick ratio of 3.61. Blueprint Medicines has a 12-month low of $43.89 and a 12-month high of $110.93. The business has a 50 day moving average of $91.77 and a 200 day moving average of $80.95.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share for the quarter, topping the consensus estimate of ($2.04) by $0.22. The firm had revenue of $71.96 million during the quarter, compared to analysts’ expectations of $67.34 million. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. The company’s revenue was up 85.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($2.65) EPS. As a group, analysts expect that Blueprint Medicines will post -5.38 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Michael Landsittel sold 5,000 shares of Blueprint Medicines stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $95.00, for a total value of $475,000.00. Following the sale, the chief financial officer now directly owns 47,286 shares in the company, valued at approximately $4,492,170. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Blueprint Medicines news, CFO Michael Landsittel sold 5,000 shares of the company’s stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $95.00, for a total transaction of $475,000.00. Following the transaction, the chief financial officer now directly owns 47,286 shares in the company, valued at approximately $4,492,170. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Christopher K. Murray sold 621 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $93.65, for a total transaction of $58,156.65. Following the transaction, the insider now directly owns 36,374 shares of the company’s stock, valued at $3,406,425.10. The disclosure for this sale can be found here. Insiders sold a total of 92,289 shares of company stock worth $8,314,163 over the last 90 days. Corporate insiders own 3.88% of the company’s stock.

Institutional Investors Weigh In On Blueprint Medicines

Several large investors have recently made changes to their positions in the business. Compass Wealth Management LLC bought a new position in shares of Blueprint Medicines during the fourth quarter valued at $69,000. PNC Financial Services Group Inc. boosted its position in shares of Blueprint Medicines by 63.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 329 shares in the last quarter. Van ECK Associates Corp lifted its position in Blueprint Medicines by 28.4% during the 4th quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 193 shares during the period. Cutler Group LLC CA increased its stake in shares of Blueprint Medicines by 1,685.7% in the 3rd quarter. Cutler Group LLC CA now owns 1,000 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 944 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Blueprint Medicines during the fourth quarter valued at approximately $95,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.